Table 2.
Outcomes of Grades 3–5 Drug-Related Adverse Events for Capecitabine-Based Versus Capecitabine-Free Combination Adjuvant Chemotherapy in Early Breast Cancer
| Grades 3–5 AEs | No. of Studies | Capecitabine Based n/N | Capecitabine Free n/N | OR [95% CI] | p |
|---|---|---|---|---|---|
| Hematologic | |||||
| Neutropenia | 7 | 1,977/4,839 | 2,460/4,836 | 0.53 (0.31–0.91) | 0.02 |
| Febrile neutropenia | 5 | 321/4,507 | 323/4,499 | 0.98 (0.54–1.79) | 0.94 |
| Anemia | 3 | 56/2,972 | 92/3,001 | 0.61 (0.43–0.85) | 0.03 |
| Thrombocytopenia | 4 | 44/2,706 | 11/2,725 | 3.39 (0.67–17.17) | 0.14 |
| Gastrointestinal | |||||
| Nausea | 5 | 111/2,632 | 117/2,671 | 0.96 (0.73–1.25) | 0.76 |
| Vomiting | 6 | 120/3,343 | 159/3,338 | 0.74 (0.58–0.94) | 0.01 |
| Diarrhea | 6 | 224/3,343 | 89/3,338 | 2.77 (1.64–4.67) | 0.0001 |
| Others | |||||
| HFS | 7 | 672/4,839 | 80/4,836 | 13.47 (6.96–26.07) | <0.001 |
| Fatigue | 5 | 311/3,204 | 309/3,199 | 1.05 (0.79–1.39) | 0.76 |
| Mucositis | 5 | 208/3,204 | 115/3,199 | 2.24 (1.17–4.30) | 0.02 |
| Myalgia | 5 | 72/3,204 | 181/3,199 | 0.42 (0.23–0.76) | 0.004 |
AEs, adverse events; HFS, hand–foot syndrome.